留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

西罗莫司的药理学作用研究进展

苏凤云 刘爱军 苏定冯

苏凤云, 刘爱军, 苏定冯. 西罗莫司的药理学作用研究进展[J]. 药学实践与服务, 2011, 29(5): 336-338,390.
引用本文: 苏凤云, 刘爱军, 苏定冯. 西罗莫司的药理学作用研究进展[J]. 药学实践与服务, 2011, 29(5): 336-338,390.
SU Feng-yun, LIU Ai-jun, SU Ding-feng. Advance in pharmacological effects of sirolimus[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 336-338,390.
Citation: SU Feng-yun, LIU Ai-jun, SU Ding-feng. Advance in pharmacological effects of sirolimus[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 336-338,390.

西罗莫司的药理学作用研究进展

基金项目: 国家自然科学基金资助项目(30901809).

Advance in pharmacological effects of sirolimus

  • 摘要: 西罗莫司(sirolimus)又名雷帕霉素(rapamycin)是一种大环内酯抗生素,目前作为免疫抑制剂已在临床上广泛使用。作为国内外研究的热点,研究发现西罗莫司具有抗炎、免疫调节、抗肿瘤、抗动脉粥样硬化、抗衰老和神经保护等多种生物活性。本文综述了其近十多年来西罗莫司药理学作用的研究进展,并对其发展前景做了展望。
  • [1] Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice[J]. Nature, 2009,460(7253):392.
    [2] Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease[J]. PLoS One, 2010,5(4):e9979.
    [3] Zhai XZ, Yao YM, Wang SH, et al. Activation of signal transducer and activator of transcription 3 in multiple organs of rats with sepsis[J]. Chin J Trauma, 2004,20(3):146.
    [4] 姚 胜,姚咏明,李红云,等. 雷帕霉素对烫伤后金黄色葡萄球菌脓毒症大鼠白细胞介素[J].中华急诊医学杂志,2006,15(1):34.
    [5] Krakauer T, Buckley M, Issaq HJ, et al. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo[J]. Antimicrob Agents Chemother, 2010,54(3):1125.
    [6] Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic[J]. Curr Opinion Invest Drugs, 2002,3(2):295.
    [7] Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis[J]. Adv Cancer Res, 2009,102:19.
    [8] Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer [J]. Gut Liver, 2010,4(4):433.
    [9] Sedrani R, Cotterns S, Kallen J. Chemical modification of rapamycin: the discovery of SDZ RAD[J]. Transplant Proc,1998,30(5):2192.
    [10] Merimsky O, Jiveliouk I, Sagi-Eisenberg R. Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma[J]. Sarcoma, 2008,2008:825093.
    [11] Tsai MK, Wu FL, Lai IR, et al. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy[J]. Int J Artif Organs, 2009, 32(6):371.
    [12] 张全胜, 史 瑞, 刘懿禾. 肝移植术后西罗莫司致间质性肺炎[J]. 中国危重病急救医学, 2010, 7:436.
    [13] Josep MC. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors[J]. Transplant Rev, 2008,22(1):73.
    [14] Fukuda D, Sata M, Tanaka K, et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells[J]. Circulation, 2005,111(7):926.
    [15] Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial[J]. Eur Heart J, 2007,28(16):1946.
    [16] Ma KL, Ruan XZ, Powis SH, et al. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells[J]. Am J Physiol Heart Circ Physiol, 2007,292(6):H2721.
    [17] Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy[J]. Annu Rev Pharmacol Toxicol, 2007,47:443.
    [18] Kuzman JA, OConnell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy[J]. Endocrinology, 2007,148(7):3477.
    [19] Soesanto W, Lin HY, Hu E, et al. Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats[J]. Hypertension,2009,54(6):1321.
    [20] Steiner JP, Connolly MA, Valentine HL, et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporine A[J]. Nat med ,1997,3(4):421.
    [21] Ruan B, Pong K, Jow F, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activitie[J]. Proc Natl Acad Sci USA, 2008,105(1):33.
    [22] Qi H, Chen Y, Fu X, et al. TOR regulates cell death induced by telomere dysfunction in budding yeast[J]. PLoS One, 2008,3(10):e3520.
    [23] Liu S, Lu B. Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster[J]. PLoS Genet, 2010,6(12):e1001237.
    [24] Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster[J]. Cell Metab, 2010,11(1):35.
    [25] Malagelada C, Jin ZH, Jackson-Lewis V, et al. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease[J]. J Neurosci, 2010,30(3):1166.
    [26] Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporineand prednisone-dependent myasthenia gravis[J]. Neurology, 2005,64(9):1641.
    [27] Phornphutkul C, Lee M, Voigt C, et al. The effect of rapamycin on bone growth in rabbits[J]. J Orthop Res, 2009,27(9):1157.
  • [1] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [2] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [3] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [4] 李清, 郭宜银, 陈颖, 瞿发林, 董文燊, 戈煜.  夜宁胶囊对小鼠镇静催眠作用及其机制的研究 . 药学实践与服务, 2024, 42(): 1-4. doi: 10.12206/j.issn.2097-2024.202211047
    [5] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [6] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [7] 张林晨, 张小琴, 张俊平.  山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
    [8] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [9] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [10] 张成中, 朱雪艳, 卜其涛, 王宏瑞, 黄宝康.  基于网络药理学与分子对接预测鸡骨草特征图谱研究 . 药学实践与服务, 2024, 42(7): 1-9. doi: 10.12206/j.issn.2097-2024.202303048
    [11] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202305011
  • 加载中
计量
  • 文章访问数:  2854
  • HTML全文浏览量:  365
  • PDF下载量:  408
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-02-28
  • 修回日期:  2011-06-29

西罗莫司的药理学作用研究进展

    基金项目:  国家自然科学基金资助项目(30901809).

摘要: 西罗莫司(sirolimus)又名雷帕霉素(rapamycin)是一种大环内酯抗生素,目前作为免疫抑制剂已在临床上广泛使用。作为国内外研究的热点,研究发现西罗莫司具有抗炎、免疫调节、抗肿瘤、抗动脉粥样硬化、抗衰老和神经保护等多种生物活性。本文综述了其近十多年来西罗莫司药理学作用的研究进展,并对其发展前景做了展望。

English Abstract

苏凤云, 刘爱军, 苏定冯. 西罗莫司的药理学作用研究进展[J]. 药学实践与服务, 2011, 29(5): 336-338,390.
引用本文: 苏凤云, 刘爱军, 苏定冯. 西罗莫司的药理学作用研究进展[J]. 药学实践与服务, 2011, 29(5): 336-338,390.
SU Feng-yun, LIU Ai-jun, SU Ding-feng. Advance in pharmacological effects of sirolimus[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 336-338,390.
Citation: SU Feng-yun, LIU Ai-jun, SU Ding-feng. Advance in pharmacological effects of sirolimus[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 336-338,390.
参考文献 (27)

目录

    /

    返回文章
    返回